Bayer
NEWS
Now in its fourth day, the American Association of Cancer Research (AACR) Annual Meeting 2018 held in Chicago, has had plenty of news, much of it preclinical or early-clinical data.
Illumina is teaming up with Loxo Oncology to develop and commercialize a multi-gene panel for broad cancer profiling. It will seek approval for a version of Illumina’s TruSight Tumor 170 as a companion diagnostic for Loxo Oncology’s larotrectinib and LOXO-292.
Eli Lilly and Company announced top-line data from its Phase III REACH-2 trial of Cyramza (ramucirumab) as a monotherapy second-line treatment for hepatocellular carcinoma (HCC), which is liver cancer.
More than a dozen advertisers, including Johnson & Johnson and Bayer, have boycotted the Fox News show, “The Ingraham Angle,” after its host, Laura Ingraham, 54, bullied high school student David Hogg.
Loxo Oncology completed the rolling submission of its New Drug Application (INDA) to the U.S. FDA for larotrectinib for adult and pediatric metastatic solid tumors with an NTRK gene fusion. What has caught many investors, analysts and industry observers off-guard is the way the company has downplayed the drug’s potential sales.
Regeneron Pharmaceuticals announced positive topline data from its Phase III PANORAMA clinical trial of Eylea (aflibercept) injection in moderately severe to severe non-proliferative diabetic retinopathy.
The company is addressing the FDA’s complaints regarding manufacturing practices, which stem from a routine inspection in January,
During an international conference in Davos, Switzerland, President Donald Trump sat down with the leaders of several European life science companies to encourage more investment in the United States.
The mom of three is now the seventh Scottish woman to join a group legal action against Bayer.
JOBS
IN THE PRESS